Scholars Central

ArticlePublished 2012

Bladder Preservation with Concurrent Radiotherapy and Gemcitabine following Maximal Transurethral Resection for Muscle Invasive Bladder Cancer: Single Institutional Experience

Authors: Mutahir A. Tunio, Mushabbab Al Asiri, Mohsin Fareed, Shoaib Ahmed, Yasser Bayoumi, Abdullah Amro

Nuclear Medicine & Radiation Therapy

Volume 3 · Issue 1 · Pages 1–5

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Abstract Objectives: For bladder preservation, cisplatinum is widely used radiosensitizer with concurrent chemoradiation (CRT). We aimed to evaluate the safety profile and potential benefit of gemcitabine as a radiosenistizer in bladder preservation. Patients and methods: During July 2006 to January 2007, consecutive 32 patients with T2-T4N0M0 bladder cancer underwent transurethral resection of bladder tumor (TURBT) followed by concurrent chemoradiation with weekly gemcitabine 100 mg/m2 . Conformal radiotherapy was given with a shrinking field technique. Complete response was defined as no visible tumor on cystoscopy and biopsy. Results: Of total, 26 patients received a median of 7 (3–8) cycles of gemcitabine and median cumulative radiation dose of 65 Gy. Grade 3 hematologic toxicities seen were; neutropenia (3.8%) and thrombocytopenia (7.7%). Grade 3 non-hematologic toxicities were; diarrhea (19.2%), nausea/vomiting (7.7%) and cystitis (15.4%). Complete response was achieved in 18 patients (69.2% [95% CI: 60–89%]). At median follow up of 36 months, four patients had local recurrences (two superficial and two muscle invasive). The overall intact bladder and overall survival rates were 75.1% and 56.3%, respectively. Conclusion: CRT with weekly gemcitabine was found feasible and highly active in the treatment of muscle invasive bladder cancer, as the 3 year intact bladder survival rates were promising.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalNuclear Medicine & Radiation Therapy
  • SubjectRadiology & Imaging
  • SubjectEnergy & Power
  • BylineArticles whose byline prints “Mutahir A. Tunio”
  • BylineArticles whose byline prints “Mushabbab Al Asiri”
  • BylineArticles whose byline prints “Mohsin Fareed”
  • BylineArticles whose byline prints “Shoaib Ahmed”
  • BylineArticles whose byline prints “Yasser Bayoumi”
  • BylineArticles whose byline prints “Abdullah Amro”